Raymond James analyst Nicholas Jansen upgraded OraSure to Outperform with a $11.25 price target following the solid Q4 report and visible revenue catalysts over the next year that should move estimates higher. The analyst sees multiple international opportunities and tailwinds in DNA Genotek that support a more positive top-line trajectory and operating expense levers for robust underlying margin and free cash flow growth combined iwth recent restructuring actions and the wind down of legal costs. Jansen sees upside to his model in 2018 from additional HCV eradication work that is stripped out of our forecasts, new royalties tied to their ancestry.com settlement and the company's global manufacturing optimization program, which could further drive profitability.